The unique functions of tissue-specific proteasomes

Trends in Biochemical Sciences

Volumn 39, Issue 1, 2014, Pages 17-24

  Kniepert, Andrea ^a   Groettrup, Marcus ^a,b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b UNIVERSITY OF KONSTANZ   (Switzerland)

Author keywords

Antigen presentation; Immunoproteasome; Spermatoproteasome; Thymoproteasome; Ubiquitin

Indexed keywords

GAMMA INTERFERON; IMMUNOPROTEASOME; PROTEASOME; SPERMATOPROTEASOME; STAT1 PROTEIN; STAT3 PROTEIN; THYMOPROTEASOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTINOBACTERIA; ANTIGEN PRESENTATION; B LYMPHOCYTE; DROSOPHILA MELANOGASTER; EPITHELIUM CELL; HELPER CELL; LISTERIA MONOCYTOGENES; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH17 CELL; THERMOPLASMA ACIDOPHILUM; THYMUS; TISSUE SPECIFICITY;

EUKARYOTA;

ANTIGEN PRESENTATION; IMMUNOPROTEASOME; SPERMATOPROTEASOME; THYMOPROTEASOME; UBIQUITIN;

ANIMALS; ANTIGEN PRESENTATION; ARCHAEAL PROTEINS; AUTOIMMUNE DISEASES; BACTERIAL PROTEINS; CELL DIFFERENTIATION; HUMANS; ORGAN SPECIFICITY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, QUATERNARY; PROTEOLYSIS; UBIQUITINATED PROTEINS;

EID: 84890859839     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2013.10.004     Document Type: Review

References (72)

1. Löwe J., et al. Crystal structure of the 20 S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995, 268:533-539.
2. Tamura T., et al. The first characterization of a eubacterial proteasome: the 20S complex of Rhodococcus. Curr. Biol. 1995, 5:766-774.
3. Groll M., et al. Structure of 20 S proteasome from yeast at 2.4A resolution. Nature 1997, 386:463-471.
4. Heinemeyer W., et al. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J. Biol. Chem. 1997, 272:25200-25209.
5. Barton L.F., et al. Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. J. Immunol. 2002, 169:3046-3052.
6. Kremer M., et al. Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J. Immunol. 2010, 185:5549-5560.
7. Khan S., et al. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J. Immunol. 2001, 167:6859-6868.
8. Groettrup M., et al. Proteasomes in immune cells: more than peptide producers?. Nat. Rev. Immunol. 2010, 10:72-77.
9. Strehl B., et al. Interferon-gamma, the functional plasticity of the ubiquitin- proteasome system, and MHC class I antigen processing. Immunol. Rev. 2005, 207:19-30.
10. Rock K.L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
11. Craiu A., et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 1997, 272:13437-13445.
12. Bai A., Forman J. The effect of the proteasome inhibitor lactacystin on the presentation of transporters associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J. Immunol. 1997, 159:2139-2146.
13. Huber E.M., et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012, 148:727-738.
14. Fehling H.J., et al. MHC class I expression in mice lacking proteasome subunit LMP-7. Science 1994, 265:1234-1237.
15. Basler M., et al. The antiviral immune response in mice devoid of immunoproteasome activity. J. Immunol. 2011, 187:5548-5557.
16. Kincaid E.Z., et al. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat. Immunol. 2012, 13:129-135.
17. Salzmann U., et al. Mutational analysis of subunit i beta 2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS Lett. 1999, 454:11-15.
18. Basler M., et al. An altered T cell repertoire in MECL-1-deficient mice. J. Immunol. 2006, 176:6665-6672.
19. Moebius J., et al. Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur. J. Immunol. 2010, 40:3439-3449.
20. Basler M., et al. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J. Immunol. 2010, 185:634-641.
21. Sijts A.J.A.M., et al. MHC class I antigen processing of an Adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. J. Immunol. 2000, 164:4500-4506.
22. Palmowski M.J., et al. Role of immunoproteasomes in cross-presentation. J. Immunol. 2006, 177:983-990.
23. + T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med. 2001, 193:1319-1326.
24. Hutchinson S., et al. A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. PLoS ONE 2011, 6:e14646.
25. Basler M., et al. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 2004, 173:3925-3934.
26. Morel S., et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000, 12:107-117.
27. Basler M., et al. Why the structure but not the activity of the immunoproteasome subunit LMP2 rescues antigen presentation. J. Immunol. 2012, 189:1868-1877.
28. Verteuil D., et al. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol. Cell. Proteomics 2010, 9:2034-2047.
29. + T cells. J. Immunol. 2006, 177:6238-6244.
30. Tu L., et al. Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur. J. Immunol. 2009, 39:3385-3394.
31. Groettrup M., et al. Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why?. Biochimie 2001, 83:367-372.
32. Zaiss D.M., et al. Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J. Immunol. 2011, 187:2302-2309.
33. Pryhuber K.G., et al. Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. J. Rheumatol. 1996, 23:747-752.
34. Kitamura A., et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J. Clin. Invest. 2011, 121:4150-4160.
35. Arima K., et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14914-14919.
36. Agarwal A.K., et al. PSMB8 encoding the beta 5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis- induced lipodystrophy syndrome. Am. J. Hum. Genet. 2010, 87:866-872.
37. Muchamuel T., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009, 15:781-787.
38. Schmidt N., et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010, 59:896-906.
39. Fitzpatrick L.R., et al. Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice. Digest Dis. Sci. 2006, 51:1269-1276.
40. Ichikawa H.T., et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis. Rheum. 2012, 64:493-503.
41. Kalim K.W., et al. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J. Immunol. 2012, 189:4182-4193.
42. Reis J., et al. The immunoproteasomes regulate LPS-induced TRIF/TRAM signaling pathway in murine macrophages. Cell Biochem. Biophys. 2011, 60:119-126.
43. Palombella V.J., et al. The ubiquitin-proteasome pathway is required for processing the NF-κB1 percursor protein and the activation of NF-κB. Cell 1994, 78:773-785.
44. Hoppe T., et al. Activation of a membrane-bound transcription factor by regulated ubiquitin/proteasome-dependent processing. Cell 2000, 102:577-586.
45. Hayashi T., Faustman D. NOD mice are defective in proteasome production and activation of NF-kappa B. Mol. Cell. Biol. 1999, 19:8646-8659.
46. Kessler B.M., et al. LMP2 expression and proteasome activity in NOD mice. Nat. Med. 2000, 6:1064.
47. Runnels H.A., et al. LMP2 expression and proteasome activity in NOD mice. Nat. Med. 2000, 6:1064-1065.
48. Seifert U., et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010, 142:613-624.
49. Nathan J.A., et al. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 2013, 152:1184-1194.
50. Prakash S., et al. An unstructured initiation site is required for efficient proteasome- mediated degradation. Nat. Struct. Mol. Biol. 2004, 11:830-837.
51. + T cell development by thymus-specific proteasomes. Science 2007, 316:1349-1353.
52. Klein L., et al. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat. Rev. Immunol. 2009, 9:833-844.
53. Nil A., et al. Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur. J. Immunol. 2004, 34:2681-2689.
54. Macagno A., et al. Dendritic cells upregulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur. J. Immunol. 1999, 29:4037-4042.
55. + T cells. Immunity 2010, 32:29-40.
56. Murata S., et al. Thymoproteasome: probable role in generating positively selecting peptides. Curr. Opin. Immunol. 2008, 20:192-196.
57. Rammensee H.G., et al. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 1993, 11:213-244.
58. Belote J.M., Zhong L. Duplicated proteasome subunit genes in Drosophila and their roles in spermatogenesis. Heredity 2009, 103:23-31.
59. Yuan X., et al. Duplicated proteasome subunit genes in Drosophila melanogaster encoding testes-specific isoforms. Genetics 1996, 144:147-157.
60. Zhong L., Belote J.M. The testis-specific proteasome subunit Pros alpha 6T of D-melanogaster is required for individualization and nuclear maturation during spermatogenesis. Development 2007, 134:3517-3525.
61. Ma J., et al. Expression of proteasome subunit isoforms during spermatogenesis in Drosophila melanogaster. Insect Mol. Biol. 2002, 11:627-639.
62. Skerget S., et al. The rhesus macaque (Macaca mulatta) sperm proteome. Mol. Cell. Proteomics 2013, 1:1.
63. Qian M.X., et al. Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis. Cell 2013, 153:1012-1024.
64. Sutovsky P., et al. Proteasomal interference prevents zona pellucida penetration and fertilization in mammals. Biol. Reprod. 2004, 71:1625-1637.
65. Ustrell V., et al. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J. 2002, 21:3516-3525.
66. Khor B., et al. Proteasome activator PA200 is required for normal spermatogenesis. Mol. Cell. Biol. 2006, 26:2999-3007.
67. Gaucher J., et al. From meiosis to postmeiotic events: the secrets of histone disappearance. FEBS J. 2010, 277:599-604.
68. Huber E.M., Groll M. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development. Angew. Chem. Int. Ed. Engl. 2012, 51:8708-8720.
69. Ho Y.K., et al. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem. Biol. 2007, 14:419-430.
70. Kuhn D.J., et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113:4667-4676.
71. Mirabella A.C., et al. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem. Biol. 2011, 18:608-618.
72. Basler M., et al. The immunoproteasome in antigen processing and other immunological functions. Cur. Opin. Immunol. 2013, 25:74-80.